Soleno Therapeutics (SLNO) Short-term Investments (2024 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Short-term Investments of $122.6 million for Q1 2026, down 41.24% year-over-year from $208.6 million in Q1 2025, and down 47.92% quarter-over-quarter from $235.4 million in Q4 2025.
Soleno Therapeutics (SLNO) Short-term Investments (2024 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Short-term Investments for 3 consecutive years, with $122.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments fell 41.24% year-over-year to $122.6 million; the TTM figure through Mar 2026 stood at $122.6 million (down 41.24% YoY), while the FY2025 annual figure was $235.4 million, up 15.65% from the prior year.
- Short-term Investments eased to $122.6 million in Q1 2026 per SLNO's latest filing, from $235.4 million in the prior quarter.
- Across five years, Short-term Investments topped out at $252.3 million in Q3 2025 and bottomed at $106.8 million in Q1 2024.
- Historically, Short-term Investments has averaged $195.2 million across 3 years, with a median of $208.6 million in 2025.
- Annual changes were most pronounced in 2025 — Short-term Investments jumped 95.32% — and 2026, when it slumped 41.24%.
- Soleno Therapeutics' Short-term Investments stood at $203.5 million in 2024, then increased by 15.65% to $235.4 million in 2025, then slumped by 47.92% to $122.6 million in 2026.
- Business Quant data shows SLNO's Short-term Investments at $122.6 million in Q1 2026, $235.4 million in Q4 2025, and $252.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122.57 Mn |
| Dec 31, 2025 | 235.37 Mn |
| Sep 30, 2025 | 252.27 Mn |
| Jun 30, 2025 | 210.34 Mn |
| Mar 31, 2025 | 208.60 Mn |
| Dec 31, 2024 | 203.51 Mn |
| Sep 30, 2024 | 208.36 Mn |
| Jun 30, 2024 | 209.10 Mn |
| Mar 31, 2024 | 106.80 Mn |